Detection of Clostridium difficile toxins A, B and binary toxin with slow off-rate modified aptamers

Diagnostic Microbiology and Infectious Disease

Volumn 76, Issue 3, 2013, Pages 278-285

  Ochsner, Urs A ^a   Katilius, Evaldas ^a   Janjic, Nebojsa ^a  

^a SomaLogic Inc   (United States)

Author keywords

Aptamer; Clostridium difficile; Diagnostic; Immunoassay; Non molecular testing; Sandwich assay; SELEX; Toxin testing; Toxins

Indexed keywords

APTAMER; BACTERIAL TOXIN; BACTERIUM ANTIBODY; BINARY TOXIN CDTA; BINARY TOXIN CDTB; CLOSTRIDIUM DIFFICILE TOXIN A; CLOSTRIDIUM DIFFICILE TOXIN B; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ARTICLE; BINDING AFFINITY; BINDING ASSAY; CHEMICAL BINDING; CLOSTRIDIUM DIFFICILE; CONTROLLED STUDY; IN VITRO SELECTION; LIMIT OF DETECTION; NONHUMAN; PRIORITY JOURNAL; RADIOASSAY; TOXIN ANALYSIS;

APTAMERS, NUCLEOTIDE; BACTERIAL PROTEINS; CLOSTRIDIUM DIFFICILE; CULTURE MEDIA, CONDITIONED; ENTEROCOLITIS, PSEUDOMEMBRANOUS; ENTEROTOXINS; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; LIMIT OF DETECTION; PEPTIDE FRAGMENTS; PROTEIN BINDING; SELEX APTAMER TECHNIQUE;

EID: 84879162539     PISSN: 07328893     EISSN: 18790070     Source Type: Journal    
DOI: 10.1016/j.diagmicrobio.2013.03.029     Document Type: Article

References (47)

1. Agaronov M., Karak S.G., Maldonado Y., Tetreault J., Aslanzadeh J. Comparison of GeneXpert PCR to BD GeneOhm for detecting C. difficile toxin gene in GDH positive toxin negative samples. Ann Clin Lab Sci 2012, 42:397-400.
2. Bacci S., Molbak K., Kjeldsen M.K., Olsen K.E. Binary toxin and death after Clostridium difficile infection. Emerg Infect Dis 2011, 17:976-982.
3. Bartlett J.G., Gerding D.N. Clinical recognition and diagnosis of Clostridium difficile infection. Clin Infect Dis 2008, 46(Suppl 1):S12-S18.
4. Bartlett J.G., Perl T.M. The new Clostridium difficile-what does it mean?. N Engl J Med 2005, 353:2503-2505.
5. Carroll K.C., Bartlett J.G. Biology of Clostridium difficile: implications for epidemiology and diagnosis. Annu Rev Microbiol 2011, 65:501-521.
6. Chapin K.C., Dickenson R.A., Wu F., Andrea S.B. Comparison of five assays for detection of Clostridium difficile toxin. J Mol Diagn 2011, 13:395-400.
7. Cohen S.H., et al. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the society for healthcare epidemiology of America (SHEA) and the infectious diseases society of America (IDSA). Infect Control Hosp Epidemiol 2010, 31:431-455.
8. Dubberke E.R., Wertheimer A.I. Review of current literature on the economic burden of Clostridium difficile infection. Infect Control Hosp Epidemiol 2009, 30:57-66.
9. Freeman J., et al. The changing epidemiology of Clostridium difficile infections. Clin Microbiol Rev 2010, 23:529-549.
10. Geric B., et al. Binary toxin-producing, large clostridial toxin-negative Clostridium difficile strains are enterotoxic but do not cause disease in hamsters. J Infect Dis 2006, 193:1143-1150.
11. Gold L., et al. Aptamer-based multiplexed proteomic technology for biomarker discovery. PLoS One 2010, 5:e15004.
12. Goorhuis A., et al. Emergence of Clostridium difficile infection due to a new hypervirulent strain, polymerase chain reaction ribotype 078. Clin Infect Dis 2008, 47:1162-1170.
13. Ho J.G., Greco A., Rupnik M., Ng K.K. Crystal structure of receptor-binding C-terminal repeats from Clostridium difficile toxin A. Proc Natl Acad Sci U S A 2005, 102:18373-18378.
14. Kuehne S.A., Cartman S.T., Heap J.T., Kelly M.L., Cockayne A., Minton N.P. The role of toxin A and toxin B in Clostridium difficile infection. Nature 2010, 467:711-713.
15. Lanis J.M., Barua S., Ballard J.D. Variations in TcdB activity and the hypervirulence of emerging strains of Clostridium difficile. PLoS Pathog 2010, 6:e1001061.
16. McFarland L.V., Mulligan M.E., Kwok R.Y., Stamm W.E. Nosocomial acquisition of Clostridium difficile infection. N Engl J Med 1989, 320:204-210.
17. Miller B.A., Chen L.F., Sexton D.J., Anderson D.J. Comparison of the burdens of hospital-onset, healthcare facility-associated Clostridium difficile Infection and of healthcare-associated infection due to methicillin-resistant Staphylococcus aureus in community hospitals. Infect Control Hosp Epidemiol 2011, 32:387-390.
18. Novak-Weekley S.M., Hollingsworth M.H. Comparison of the premier toxin A and B assay and the TOX A/B II assay for diagnosis of Clostridium difficile infection. Clin Vaccine Immunol 2008, 15:575-578.
19. Novak-Weekley S.M., et al. Clostridium difficile testing in the clinical laboratory by use of multiple testing algorithms. J Clin Microbiol 2010, 48:889-893.
20. Pancholi P., Kelly C., Raczkowski M., Balada-Llasat J.M. Detection of toxigenic Clostridium difficile: comparison of the cell culture neutralization, Xpert C. difficile, Xpert C. difficile/Epi, and Illumigene C. difficile assays. J Clin Microbiol 2012, 50:1331-1335.
21. Pepin J., Valiquette L., Cossette B. Mortality attributable to nosocomial Clostridium difficile-associated disease during an epidemic caused by a hypervirulent strain in Quebec. CMAJ 2005, 173:1037-1042.
22. Perelle S., Gibert M., Bourlioux P., Corthier G., Popoff M.R. Production of a complete binary toxin (actin-specific ADP-ribosyltransferase) by Clostridium difficile CD196. Infect Immun 1997, 65:1402-1407.
23. Pfeifer G., et al. Cellular uptake of Clostridium difficile toxin B. Translocation of the N-terminal catalytic domain into the cytosol of eukaryotic cells. J Biol Chem 2003, 278:44535-44541.
24. Planche T., et al. Diagnosis of Clostridium difficile infection by toxin detection kits: a systematic review. Lancet Infect Dis 2008, 8:777-784.
25. Pruitt R.N., Lacy D.B. Toward a structural understanding of Clostridium difficile toxins A and B. Front Cell Infect Microbiol 2012, 2:28.
26. Reinert D.J., Jank T., Aktories K., Schulz G.E. Structural basis for the function of Clostridium difficile toxin B. J Mol Biol 2005, 351:973-981.
27. Riggs M.M., Sethi A.K., Zabarsky T.F., Eckstein E.C., Jump R.L., Donskey C.J. Asymptomatic carriers are a potential source for transmission of epidemic and nonepidemic Clostridium difficile strains among long-term care facility residents. Clin Infect Dis 2007, 45:992-998.
28. Rupnik M., Avesani V., Janc M., von Eichel-Streiber C., Delmee M. A novel toxinotyping scheme and correlation of toxinotypes with serogroups of Clostridium difficile isolates. J Clin Microbiol 1998, 36:2240-2247.
29. Rupnik M., Grabnar M., Geric B. Binary toxin producing Clostridium difficile strains. Anaerobe 2003, 9:289-294.
30. Rupnik M., Wilcox M.H., Gerding D.N. Clostridium difficile infection: new developments in epidemiology and pathogenesis. Nat Rev Microbiol 2009, 7:526-536.
31. Samra Z., Luzon A., Bishara J. Evaluation of two rapid immunochromatography tests for the detection of Clostridium difficile toxins. Dig Dis Sci 2008, 53:1876-1879.
32. Schwan C., et al. Clostridium difficile toxin CDT induces formation of microtubule-based protrusions and increases adherence of bacteria. PLoS Pathog 2009, 5:e1000626.
33. Stabler R.A., et al. Comparative genome and phenotypic analysis of Clostridium difficile 027 strains provides insight into the evolution of a hypervirulent bacterium. Genome Biol 2009, 10:R102.
34. Stevens V., Dumyati G., Fine L.S., Fisher S.G., van Wijngaarden E. Cumulative antibiotic exposures over time and the risk of Clostridium difficile infection. Clin Infect Dis 2011, 53:42-48.
35. Stewart D.B., Berg A., Hegarty J. Predicting recurrence of C. difficile colitis using bacterial virulence factors: binary toxin is the key. J Gastrointest Surg 2012.
36. Sundriyal A., Roberts A.K., Ling R., McGlashan J., Shone C.C., Acharya K.R. Expression, purification and cell cytotoxicity of actin-modifying binary toxin from Clostridium difficile. Protein Expr Purif 2010, 74:42-48.
37. Sundriyal A., Roberts A.K., Shone C.C., Acharya K.R. Structural basis for substrate recognition in the enzymatic component of ADP-ribosyltransferase toxin CDTa from Clostridium difficile. J Biol Chem 2009, 284:28713-28719.
38. Sunenshine R.H., McDonald L.C. Clostridium difficile-associated disease: new challenges from an established pathogen. Cleve Clin J Med 2006, 73:187-197.
39. Tenover F.C., Baron E.J., Peterson L.R., Persing D.H. Laboratory diagnosis of Clostridium difficile infection can molecular amplification methods move us out of uncertainty?. J Mol Diagn 2011, 13:573-582.
40. Thomas C., Stevenson M., Riley T.V. Antibiotics and hospital-acquired Clostridium difficile-associated diarrhoea: a systematic review. J Antimicrob Chemother 2003, 51:1339-1350.
41. Ticehurst J.R., Aird D.Z., Dam L.M., Borek A.P., Hargrove J.T., Carroll K.C. Effective detection of toxigenic Clostridium difficile by a two-step algorithm including tests for antigen and cytotoxin. J Clin Microbiol 2006, 44:1145-1149.
42. Vaught J.D., et al. Expanding the chemistry of DNA for in vitro selection. J Am Chem Soc 2010, 132:4141-4151.
43. Viala C., Le Monnier A., Maataoui N., Rousseau C., Collignon A., Poilane I. Comparison of commercial molecular assays for toxigenic Clostridium difficile detection in stools: BD GeneOhm Cdiff XPert C. difficile and illumigene C. difficile. J Microbiol Methods 2012, 90:83-85.
44. Voth D.E., Ballard J.D. Clostridium difficile toxins: mechanism of action and role in disease. Clin Microbiol Rev 2005, 18:247-263.
45. Warny M., et al. Toxin production by an emerging strain of Clostridium difficile associated with outbreaks of severe disease in North America and Europe. Lancet 2005, 366:1079-1084.
46. Wilcox M.H., Planche T., Fang F.C., Gilligan P. What is the current role of algorithmic approaches for diagnosis of Clostridium difficile infection?. J Clin Microbiol 2010, 48:4347-4353.
47. Williamson D.A., Basu I., Freeman J., Swager T., Roberts S.A. Improved detection of toxigenic Clostridium difficile using the Cepheid Xpert C difficile assay and impact on C difficile infection rates in a tertiary hospital: A double-edged sword. Am J Infect Control 2012, 41:270-272.